Status:
ACTIVE_NOT_RECRUITING
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Lead Sponsor:
Mirati Therapeutics Inc.
Conditions:
Metastatic Non Small Cell Lung Cancer
Advanced Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutat...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed diagnosis of NSCLC with KRAS G12C mutation.
- Candidacy to receive treatment with docetaxel.
- Crossover
- Evidence of RECIST 1.1 defined disease progression on docetaxel per BICR
- ECOG performance status 0-2
Exclusion
- Prior treatment with an agent targeting KRAS G12C (e.g., AMG 510, Sotorasib).
- Active brain metastases.
- Crossover
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2026
Estimated Enrollment :
453 Patients enrolled
Trial Details
Trial ID
NCT04685135
Start Date
February 23 2021
End Date
July 2 2026
Last Update
January 22 2025
Active Locations (343)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 012-898
Cerritos, California, United States, 90703
2
City of Hope - Duarte (Main Campus)
Duarte, California, United States, 91010
3
Local Institution - 012-898 D
Glendale, California, United States, 91204
4
Local Institution - 012-910-A
Huntington Beach, California, United States, 92648